Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Multicentre, Randomised, Double-blind, Placebo-controlled Study of Verinurad and Allopurinol in Patients With Chronic KIdney Disease and Hyperuricaemia

NCT03990363 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT03990363
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03990363 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Multicentre, Randomised, Double-blind, Placebo-controlled Study of Verinurad and Allopurinol in Patients With Chronic KIdney Disease and Hyperuricaemia
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
July 23, 2019
Completion date
November 22, 2021
Enrollment
861 (actual)
Sites
165

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease